CC vs CF
The Chemours Company vs CF Industries — AI-powered side-by-side comparison
CC
The Chemours Company
44
Reduce
VS
| Metric | CC | CF |
|---|
| AI Score |
44
|
69
|
| Price |
$14.81
|
$117.79
|
| P/E Ratio |
-7.40×
|
8.71×
|
| ROE |
-154.4%
|
30.1%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
15.3%
|
42.5%
|
| Debt / Equity |
-82.92×
|
0.63×
|
| Dividend Yield |
2.4%
|
1.7%
|
| RSI (14) |
36.7
|
54.7
|
| Beta |
1.428
|
0.398
|
| Expected Upside |
—
|
+7.3%
|
AI Committee View
Current Innellis committee reasoning for CC versus CF.
CF leads by 25 points.
CF scores 69/100 (Buy) versus CC at 44/100 (Reduce).
CC Committee View
50% agreement
6 analysts
The committee is genuinely divided. Macro Analyst sees a compelling case — vix regime is low -- calm backdrop supports risk-taking. Growth Analyst remains cautious — revenue declining -1.4% yoy -- this is not a growth story right now. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- VIX regime is low -- calm backdrop supports risk-taking — Macro
- Market regime is bullish (Bull market -- normal position sizing) — Macro
- Beta of 1.37 means this name should amplify a favorable market regime — Macro
Bear Case
- Price-to-book of 7.1x prices in significant intangible value — Value
- ROE of only -164.4% -- cheap may mean cheap for a reason — Value
- Debt-to-equity of 16.56 adds balance-sheet risk to the value case — Value
CF Committee View
80% agreement
5 analysts
The primary driver is eps growing 76.3% yoy. The main limiting factor is macd histogram negative -- bearish momentum. The committee is constructive but not yet at full conviction.
Bull Case
- P/E of 8.5 is inexpensive for the broad market — Value
- ROE of 40.4% shows genuine earnings power backing the valuation — Value
- EPS growing 76.3% YoY — Growth
Bear Case
- MACD histogram negative -- bearish momentum — Technical
- Price structure (LH_LL) contradicts the uptrend -- mixed signals — Technical